Transcript PowerPoint-præsentation

FAC U LTY O F H EALT H AN D M E D I CAL S C I E N C E S
U N IVE RS ITY O F C O PE NHAG E N
Healthcare costs in the Danish randomised controlled lung cancer CT-screening trial: a registry study
Jakob F Rasmussen,1 Volkert Siersma,1 Jesper H Pedersen,2 Bruno Heleno,1 Zaigham Saghir,2 John Brodersen 1
1The
Research Unit for General Practice and Section of General Practice, University of Copenhagen, 2 Department of Cardiothoracic Surgery, RT 2152, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, 2100 Copenhagen,
Aim
To analyse healthcare costs of participants in the Danish lung
cancer CT-screening trial (DLCST).
2000
1800
p<.0001
1600
p=0.52
1400
Conclusion
1200
USD
CT screening increases healthcare costs compared with no
screening; this increase is fully explained by the costs of the CTscreening scans.
CT group
Control group
1000
800
600
400
Overall healthcare costs were higher for the true-positive and
false-positive groups than for the control group, also when
excluding CT-screening scan costs.
200
0
Incl. CT-screening scan
Excl. CT-screening scan
Figure 2: Comparison of annual healthcare costs per
participant in the CT-screening group and the control group
in the DLCST
Background
Low dose computerised tomography (CT) screening for lung
cancer can reduce lung cancer mortality but more data on costeffectiveness are needed before recommendations can be made.
Method
This study analysed data of participants in the DLCST(figure 1).
In Denmark all healthcare costs and services are recorded in public
registries.
Residents in Denmark have a unique personal identification
number and every event in the public healthcare system is linked
to this number
Figure 1: Design of the Danish Lung Cancer Screening Trial
Healthcare cost data for both the primary and the secondary
healthcare sector were retrieved from public registries from
randomisation (2004-2006) until September 2011.
Results
Costs in the randomised groups are presented in figure 2. In the
diagnostic groups, costs were 10.57 (95% CI 7.09 to15.75) times
higher for the true-positive and 1.67 (95% CI 1.20 to 2.32) times
higher for the false-positive group compared with the control
group.
Presenting author: Jakob Fraes Rasmussen
e: [email protected]
m: +45 50998393
Figure 3: Mean annual healthcare costs per participant in the
control group and the diagnostic groups in the DLCST during five
screening rounds